Kim et al. used doxycycline-inducible CRISPR/Cas9 as a therapeutic tool to target KRAS G12V, G12D, and G13D in CRC cells both in vitro and in vivo, demonstrating that a 7.2-fold reduction in tumor volume was achieved by the knockdown of G12V mutant by highly specific KRAS G12V single-guide RNA (sgRNA) in a xenograft model without altering the wild-type allele (Figure 1 and ref. 46). This evidence concerns the gene KRAS and neoplasm.